Pharmasurgics To Begin Phase II Clinical Trial For Prevention Of Post-Surgical Adhesions

Main Category: Dermatology
Also Included In: Preventive Medicine;  Clinical Trials / Drug Trials;  Pharma Industry / Biotech Industry
Article Date: 04 Dec 2009 - 3:00 PDT

email to a friend   printer friendly   opinions  

Pharmasurgics AB - part of the Karolinska Development dermatology and wound healing company "Pergamum" announced that Pharmasurgics has received approval from the Swedish Medical Products Agency to begin a Phase II clinical trial. The trial will begin in December 2009 and will monitor the safety and efficacy of PharmaSurgics' novel candidate drug for the prevention of post-surgical adhesions in patients undergoing hand surgery. Post-surgical adhesions are bands of scar tissue connecting anatomic sites in the body that should not normally be connected. These develop after almost every type of surgery and can cause severe symptoms. PXL01 is based on an endogenous human peptide with pronounced anti-inflammatory and antimicrobial effects. It is formulated in a gel that provides a burst of the active pharmaceutical ingredient directly after application combined with slow release during the healing period.

PharmaSurgics' Managing Director, Margit Mahlapuu , said, "Entering Phase II development is an important milestone for the company. It follows a strong preclinical program and good safety and tolerability results from the Phase I trial. Current treatment options for preventing post-surgical adhesions are all based on physical barriers and have failed to meet the efficacy levels demanded by surgeons. PXL01 has the potential to deliver improved efficacy and to become the first anti-adhesion product on the market based on pharmaceutical properties."

Jorgen Thorball, Pergamum's Chairman, commented, "PharmaSurgics has developed an extremely interesting and novel approach in a market with significant unmet medical needs. Success in the Phase II proof-of-concept study will enable the development of similar treatments for a very broad range of surgical procedures. Considering the substantial costs that post-surgical adhesions represent in today's healthcare systems there is tremendous market potential for new, more efficacious treatments."

The Phase II clinical trial will monitor the safety and document the efficacy of PXL01 in reducing adhesion formation following flexor tendon repair surgery. This indication allows for measurement of objective endpoints, rather than subjective measurements of pain. The objective of the efficacy part of the study is to see an improvement in finger strength and mobility compared to placebo following surgery. The prospective, randomized, double-blind and placebo-controlled trial will be conducted at three of Sweden's leading hand surgery clinics and will include approximately 140 patients.

Conny Bogentoft, CEO of Karolinska Development, said, "PharmaSurgics is making excellent progress. It also provides a good example of how Karolinska Development's business model is able to take a scientific concept from bench to clinical development extremely quickly and efficiently. Our overall portfolio, and particularly the Pergamum group, continues to go from strength to strength as more companies reach Phase II."

About PharmaSurgics

PharmaSurgics in Sweden AB is a biotech company that develops and commercializes novel treatments for the prevention of harmful scarring and promotion of wound healing after surgery. PharmaSurgics' product concept is based on proprietary synthetic peptides which have strong anti-inflammatory and anti-infectious properties. The company is located in Gothenburg, Sweden and was founded in 2005 based on extensive research by Dr. Inger Mattsby-Baltzer and Professor Kjell Olmarker at Sahlgrenska University Hospital, Gothenburg, Sweden. PharmaSurgics is part of the Pergamum group of companies.

Source: PharmaSurgics AB

• Additional
• References
• Citations